Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards – BioSpace

Posted: Published on January 31st, 2021

This post was added by Alex Diaz-Granados

Leading experts in central nervous system (CNS) clinical development and translational sciences to advise companys advancement of therapeutic pipeline candidates

CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics.

We are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and translational science, as well as CNS disease biology. The advisors expertise will be highly valuable for optimizing the development path and therapeutic potential of the companys pipeline including CY6463, our first-in-class CNS-penetrant sGC stimulator, said Andreas Busch, Ph.D., Chief Scientific Officer of Cyclerion.

I look forward to working closely with our advisors to advance our promising pipeline, starting first with ADv and MELAS and to explore additional indications associated with cognitive impairment, saidChristopher Wright, M.D., Chief Medical Officer of Cyclerion.

Clinical Advisory Board:

Scientific Advisory Board:

AboutCyclerion Therapeutics Cyclerion Therapeuticsis a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerions lead program is CY6463, a first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive impairment and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).

For more information about Cyclerion, please visithttps://www.cyclerion.com/and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Forward Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. We may, in some cases use terms such as predicts, believes, potential, continue, anticipates, estimates, expects, plans, intends, may, could, might, likely, will, should or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading Risk Factors and elsewhere in our 2019 Form 10-K filed onMarch 12, 2020, and in Cyclerions subsequentSECfilings, including the Form 10-Qs filed onMay 4, 2020,August 3, 2020andNovember 5, 2020. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Cyclerion undertakes no obligation to update these forward-looking statements, except as required by law.

Investors Carlo Tanzi, Ph.D. Kendall Investor Relations ctanzi@kendallir.com

Go here to read the rest:
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - BioSpace

Related Posts
This entry was posted in Vascular Biology. Bookmark the permalink.

Comments are closed.